Startseite » Vaccine studies

We are looking for participants for vaccine studies

Impfstudie_Tropeninstitut
Copyright: LMU University Hospital Munich


Improved protection against infectious diseases through vaccination
has been an important topic at our institute for many years. Together with renowned vaccine developers, we have been researching and working on new developments and improvements of vaccines for almost 20 years.

Important goals of our clinical studies are e.g. to test the efficacy and safety of a vaccine, to advance improvements, to gain further scientific knowledge as well as to break innovative ground in the field of vaccination.

To be able to conduct studies, we rely on your support:


We are looking for volunteers aged 18 years and older.

If you are interested we look forward to receiving your non-binding registration by e-mail at: 
impfstudien@lrz.uni-muenchen.de


For registration we ask for the following information:

  • Name, first name
  • Date of birth
  • Cell phone number


Your data will be kept strictly confidential and will not be passed on to third parties.


Here you will find an overview of our ongoing vaccination studies

Current or soon to start vaccination studies

Further details will be announced shortly.


Vaccination studies: recruitment completed

 

Thank you for your interest!

Your study team at the Institute of Infectious and Tropical Medicine, Munich, Germany


Contact

Study coordination 
LMU University Hospital
Division of Infectious Diseases and Tropical Medicine
Leopoldstrasse 5
80802 Munich, Germany

Phone: +49 (0)89 4400 59850
E-Mail: impfstudien@lrz.uni-muenchen.de



Impfstudie_Tropeninstitut_2 Impfstudie_Tropeninstitut_3


Publications

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2.
Kremsner, P.G., Mann, P., Kroidl, A. et al., Wien Klin Wochenschr (2021). https://doi.org/10.1007/s00508-021-01922-y

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers
, Peter Kremsner, Philipp Mann, Jacobus Bosch, Rolf Fendel, Julian J. Gabor, Andrea Kreidenweiss, Arne Kroidl, Isabel Leroux-Roels, Geert Leroux-Roels, Christoph Schindler, Mirjam Schunk, Thirumalaisamy P. Velavan, Mariola Fotin-Mleczek, Stefan Müller, Gianluca Quintini, Oliver Schönborn-Kellenberger, Dominik Vahrenhorst, Thomas Verstraeten, Lisa Walz, Olaf-Oliver Wolz, Lidia Oostvogels
medRxiv 2020.11.09.20228551; https://doi.org/10.1101/2020.11.09.20228551

Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial, Cassandra Aldrich, Isabel Leroux–Roels, Katell Bidet Huang, Mihai Alexandru Bica, Edde Loeliger, Oliver Schoenborn-Kellenberger, Lisa Walz, Geert Leroux-Roels, Frank von Sonnenburg, Lidia Oostvogels, Vaccine, Volume 39, Issue 8, 2021, Pages 1310-1318, ISSN 0264-410X, https://doi.org/10.1016/j.vaccine.2020.12.070


Impfstudie_Tropeninstitut_5



Looking for participants for yellow fever vaccination study 2021

For our new yellow fever vaccine trial starting in September 2021, we are testing a novel yellow fever vaccine (Phase II) against the conventional yellow fever vaccine. [more...]